Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

Michael W. Deininger, Kenneth J. Kopecky, Jerald P. Radich, Suzanne Kamel-Reid, Wendy Stock, Elisabeth Paietta, Peter D. Emanuel, Martin Tallman, Martha Wadleigh, Richard A. Larson, Jeffrey H. Lipton, Marilyn L. Slovak, Frederick R. Appelbaum, Brian J. Druker

Research output: Contribution to journal › Article › peer-review

55 Scopus citations

Fingerprint

Dive into the research topics of 'Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia'. Together they form a unique fingerprint.

Medicine & Life Sciences